OneMedNet (ONMD) Q4 2024 earnings summary

Executive summary

• Revenue declined 37% year-over-year to $0.6 million, driven by the planned discontinuation of the BEAM platform and a strategic shift to iRWD sales.

• Net loss improved to $10.1 million from $33.8 million in 2023, reflecting lower operating expenses and reduced non-cash charges.

• The company completed a business combination in November 2023 and raised $6.3 million in private placements in 2024.

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring losses and limited liquidity.

Financial highlights

• Total revenue for 2024 was $0.6 million, down from $1.0 million in 2023.

• Gross margin was negative, with cost of revenue exceeding total revenue.

• Operating expenses totaled $9.3 million, up 39% year-over-year, mainly due to increased public company costs.

• Net loss per share was $(0.36) compared to $(4.65) in 2023.

• Cash and cash equivalents at year-end were $0.2 million, with $2.8 million in Bitcoin holdings.

Outlook and guidance

• Management does not believe current cash is sufficient for the next 12 months and is seeking additional financing.

• The company plans to focus on expanding iRWD sales and global reach, targeting life sciences, AI, and medical device markets.